Reata Pharmaceuticals Company

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl (“bardoxolone”) and omaveloxolone, target the important transcription factor Nrf2 that promotes restoration of mitochondrial function, reduction of oxidative stress, and inhibition of pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.
Industry: Small&Large Molecules
Headquarters: Irving, Texas, United States
Founded Date: 2002
Employees Number: 51-100
Funding Status: IPO
Investors Number: 9
Total Funding: 1,33E+09
Estimated Revenue: $1M to $10M
Last Funding Date: 11 06 20
Last Funding Type: Post-IPO Equity

Visit Website
Register and Claim Ownership